RxDoctor Payments DataLook up a doctor →

Jason Zagrodzky, MD

Clinical Cardiac Electrophysiology · Austin, TXNPI 1912982018

Payments from drug & device makers

$960,858in general payments, 2019–2025

Across 1,208 payments — averaging $795.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Haemonetics Corporation$330K
  • Medical Device Business Services, Inc.$286K
  • Biosense Webster, Inc.$276K
  • Sanofi-aventis U.S. LLC$26K
  • Abbott$24K
  • Johnson & Johnson$6K
  • plus $13K from 19 others

What the payments were for

  • Consulting fees$574,55760%
  • Speaking & faculty fees$35,1744%
  • Travel & lodging$18,0422%
  • Food & beverage$25,4063%
  • Education$360%
  • Other$307,64432%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$960,858 in reported general payments places this provider in the 95th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$600,138
Medicare patients
802
Services billed
5,476

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban300$281,585
XareltoRivaroxaban195$173,281
MultaqDronedarone Hcl60$51,640
Propafenone Hcl ErPropafenone Hcl31$4,510
Dabigatran EtexilateDabigatran Etexilate Mesylate11$4,317
Amiodarone Hcl59$2,918
Metoprolol Succinate124$2,089
Flecainide Acetate66$2,045
Mexiletine Hcl23$1,464
Diltiazem 24hr Er (Cd)Diltiazem Hcl44$884
SotalolSotalol Hcl43$828
Nebivolol Hcl15$684
Propafenone Hcl22$670
Pantoprazole Sodium136$354
ClopidogrelClopidogrel Bisulfate35$308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,657$281,585300 claims
Johnson & JohnsonXarelto$5,729$173,281195 claims
Sanofi-aventis U.S. LLCMultaq$26,287$51,64060 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →